Nature Communications (Jan 2020)
Integrative discovery of treatments for high-risk neuroblastoma
- Elin Almstedt,
- Ramy Elgendy,
- Neda Hekmati,
- Emil Rosén,
- Caroline Wärn,
- Thale Kristin Olsen,
- Cecilia Dyberg,
- Milena Doroszko,
- Ida Larsson,
- Anders Sundström,
- Marie Arsenian Henriksson,
- Sven Påhlman,
- Daniel Bexell,
- Michael Vanlandewijck,
- Per Kogner,
- Rebecka Jörnsten,
- Cecilia Krona,
- Sven Nelander
Affiliations
- Elin Almstedt
- Department of Immunology, Genetics and Pathology, Uppsala University
- Ramy Elgendy
- Department of Immunology, Genetics and Pathology, Uppsala University
- Neda Hekmati
- Department of Immunology, Genetics and Pathology, Uppsala University
- Emil Rosén
- Department of Immunology, Genetics and Pathology, Uppsala University
- Caroline Wärn
- Department of Immunology, Genetics and Pathology, Uppsala University
- Thale Kristin Olsen
- Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet
- Cecilia Dyberg
- Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet
- Milena Doroszko
- Department of Immunology, Genetics and Pathology, Uppsala University
- Ida Larsson
- Department of Immunology, Genetics and Pathology, Uppsala University
- Anders Sundström
- Department of Immunology, Genetics and Pathology, Uppsala University
- Marie Arsenian Henriksson
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
- Sven Påhlman
- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University
- Daniel Bexell
- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University
- Michael Vanlandewijck
- Department of Immunology, Genetics and Pathology, Uppsala University
- Per Kogner
- Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet
- Rebecka Jörnsten
- Mathematical Sciences, Chalmers University of Technology
- Cecilia Krona
- Department of Immunology, Genetics and Pathology, Uppsala University
- Sven Nelander
- Department of Immunology, Genetics and Pathology, Uppsala University
- DOI
- https://doi.org/10.1038/s41467-019-13817-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
We lack effective treatment for half of children with high-risk neuroblastoma. Here, the authors introduce an algorithm that can predict the effect of interventions on gene expression signatures associated with high disease processes and risk, and identify and validate promising drug targets.
